ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0662

Cause-Specific Mortality in Patients with Gout in the Veteran’s Health Administration: A Matched Cohort Study

Lindsay Helget1, Bryant England1, Punyasha Roul1, Harlan Sayles1, Alison Petro1 and Ted Mikuls1, 1University of Nebraska Medical Center, Omaha, NE

Meeting: ACR Convergence 2020

Keywords: gout, Mortality, risk factors

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 7, 2020

Title: Metabolic & Crystal Arthropathies Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Gout is the most common type of inflammatory arthritis, with a prevalence in the Veteran’s Health Administration (VHA) of nearly 6%.   While gout flares prompt patients to seek medical attention, the longer-term consequences of gout are important considerations for patients, clinicians, and health systems.  Associated with increased all-cause mortality, an understanding of the cause-specific mortality risk in gout remains incomplete.  The purpose of this study was to compare all-cause and cause-specific mortality risk between gout and non-gout patients in the VHA.

Methods: We performed a retrospective, matched cohort study, identifying patients with gout using the VHA administrative data from 1/1999-9/2015 based on the presence of ≥2 ICD-9 codes for gout (274.X).  The index date was defined as the date of the 2nd diagnostic code.  Gout patients were matched up to 1:10 on birth year, sex, and year of VHA enrollment with non-gout patients (no prior diagnostic codes or urate lowering therapy). Patients were followed from the index date until death, censoring due to end of study period or subsequently fulfilling the gout algorithm (non-gout patients could cross-over and contribute to gout “at risk” observation). Vital status and cause of death (20 unique ICD-10 chapters) were obtained from the National Death Index (through 12/2017). Associations of gout with all-cause and cause-specific mortality were examined using Cox regression. 

Results: Gout patients (n = 559,253) were matched to 5,431,582 non-gout controls. Gout patients had a higher BMI and greater comorbidity (Table 1). There were 246,291 deaths over 4,250,477 patient-years in gout patients and 1,995,863 deaths over 40,469,354 patient-years of follow-up in controls.  Associations of gout with all-cause and cause-specific mortality are shown in Figure 1.  The strongest associations of gout with cause-specific mortality were observed with genitourinary conditions. Kidney failure was the most common specific cause of death in this category. Of the 20 unique ICD-10 chapters examined, mortality was increased among gout patients for 8 specific causes.  In contrast, gout patients were at lower risk from death related to neurologic (e.g., Alzheimer’s, Parkinson’s, and other neurodegenerative disorders), mental health, respiratory, and malignancy related conditions.

Conclusion: Using data from the largest integrated health system in the U.S, we found that gout patients in the VHA have an ~10% higher rate of all-cause mortality.  Although patients with gout are well recognized to have higher all-cause and cardiovascular mortality, these results suggest that survival is negatively impacted by a number of other health conditions with genitourinary causes acting as the most over-represented cause of death in gout.  Likewise, these data suggest that gout patients exhibit a survival advantage for both neurologic and mental health causes. Additional research examining factors associated with cause-specific survival in this Veteran population are needed as this could inform future strategies aimed at improving long-term outcomes in gout.


Disclosure: L. Helget, None; B. England, None; P. Roul, None; H. Sayles, None; A. Petro, None; T. Mikuls, Horizon Therapeutics, 2.

To cite this abstract in AMA style:

Helget L, England B, Roul P, Sayles H, Petro A, Mikuls T. Cause-Specific Mortality in Patients with Gout in the Veteran’s Health Administration: A Matched Cohort Study [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/cause-specific-mortality-in-patients-with-gout-in-the-veterans-health-administration-a-matched-cohort-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cause-specific-mortality-in-patients-with-gout-in-the-veterans-health-administration-a-matched-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology